These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10070890)

  • 1. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
    Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
    Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.
    Hughes AN; Rafi I; Griffin MJ; Calvert AH; Newell DR; Calvete JA; Johnston A; Clendeninn N; Boddy AV
    Clin Cancer Res; 1999 Jan; 5(1):111-8. PubMed ID: 9918208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
    Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
    Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation.
    Estlin EJ; Pinkerton CR; Lewis IJ; Lashford L; McDowell H; Morland B; Kohler J; Newell DR; Boddy AV; Taylor GA; Price L; Ablett S; Hobson R; Pitsiladis M; Brampton M; Clendeninn N; Johnston A; Pearson AD
    Br J Cancer; 2001 Jan; 84(1):11-8. PubMed ID: 11139306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
    Rafi I; Boddy AV; Calvete JA; Taylor GA; Newell DR; Bailey NP; Lind MJ; Green M; Hines J; Johnstone A; Clendeninn N; Calvert AH
    J Clin Oncol; 1998 Mar; 16(3):1131-41. PubMed ID: 9508200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma.
    Stuart K; Tessitore J; Rudy J; Clendennin N; Johnston A
    Cancer; 1999 Aug; 86(3):410-4. PubMed ID: 10430248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.
    Hughes AN; Griffin MJ; Newell DR; Calvert AH; Johnston A; Kerr B; Lee C; Liang B; Boddy AV
    Br J Cancer; 2000 May; 82(9):1519-27. PubMed ID: 10789718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
    Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
    Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
    Rees C; Beale P; Trigo JM; Mitchell F; Jackman A; Smith R; Douglass E; Judson I
    Clin Cancer Res; 2003 Jun; 9(6):2049-55. PubMed ID: 12796367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
    Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
    Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
    J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
    Jhawer M; Rosen L; Dancey J; Hochster H; Hamburg S; Tempero M; Clendeninn N; Mani S
    Invest New Drugs; 2007 Feb; 25(1):85-94. PubMed ID: 16957834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymitaq (Zarix).
    Niculescu-Duvaz I
    Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Measurement of plasma concentration and bioavailability of nolatrexed dihydrochloride in mice].
    Wang GF; Zhang JY; Wu SY; Xu W; Wan SH; Shao CF; Zhang JJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Nov; 28(11):1993-5. PubMed ID: 19033111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
    Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.